Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION:
Melflufen has potential to fill a gap in the myeloma treatment landscape by providing a new mechanism of action with clinically meaningful efficacy and a favorable safety profile in patients refractory to multiple novel agents.
|
Authors | Albert Oriol, Alessandra Larocca, Xavier Leleu, Roman Hajek, Hani Hassoun, Paula Rodríguez-Otero, Agne Paner, Fredrik H Schjesvold, Joachim Gullbo, Paul G Richardson |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 29
Issue 10
Pg. 1069-1078
(Oct 2020)
ISSN: 1744-7658 [Electronic] England |
PMID | 32924646
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- melflufen
- Phenylalanine
- Melphalan
|
Topics |
- Antineoplastic Agents, Alkylating
(administration & dosage, adverse effects, pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, pharmacology)
- Humans
- Melphalan
(administration & dosage, adverse effects, analogs & derivatives, pharmacology)
- Multiple Myeloma
(drug therapy, pathology)
- Phenylalanine
(administration & dosage, adverse effects, analogs & derivatives, pharmacology)
- Recurrence
- Survival Rate
|